Opus Genetics, Inc. Payments of Debt Issuance Costs
Opus Genetics, Inc. (IRD) reported Payments of Debt Issuance Costs of $1.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-06
- Opus Genetics, Inc. payments of debt issuance costs for fiscal 2020 was $10.00K, a 400.00% increase from fiscal 2019.
- Opus Genetics, Inc. payments of debt issuance costs for fiscal 2019 was $2.00K.
| Period end | Payments of Debt Issuance Costs | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|
| 2026-06-30 | $1.11M 10-Q · filed 2026-08-06 | ||
| 2026-04-02 | $1.10M 10-Q · filed 2026-08-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | ||
| 2020-12-31 | $10.00K 10-K · filed 2021-03-11 | ||
| 2019-12-31 | $2.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |